JP2015518705A - ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド - Google Patents
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド Download PDFInfo
- Publication number
- JP2015518705A JP2015518705A JP2015504565A JP2015504565A JP2015518705A JP 2015518705 A JP2015518705 A JP 2015518705A JP 2015504565 A JP2015504565 A JP 2015504565A JP 2015504565 A JP2015504565 A JP 2015504565A JP 2015518705 A JP2015518705 A JP 2015518705A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently
- polynucleotide
- alkyl
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (101)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261618957P | 2012-04-02 | 2012-04-02 | |
US201261618896P | 2012-04-02 | 2012-04-02 | |
US201261618953P | 2012-04-02 | 2012-04-02 | |
US201261618866P | 2012-04-02 | 2012-04-02 | |
US201261618961P | 2012-04-02 | 2012-04-02 | |
US201261618878P | 2012-04-02 | 2012-04-02 | |
US201261618868P | 2012-04-02 | 2012-04-02 | |
US201261618945P | 2012-04-02 | 2012-04-02 | |
US201261618870P | 2012-04-02 | 2012-04-02 | |
US201261618911P | 2012-04-02 | 2012-04-02 | |
US201261618862P | 2012-04-02 | 2012-04-02 | |
US201261618885P | 2012-04-02 | 2012-04-02 | |
US201261618873P | 2012-04-02 | 2012-04-02 | |
US201261618922P | 2012-04-02 | 2012-04-02 | |
US61/618,945 | 2012-04-02 | ||
US61/618,961 | 2012-04-02 | ||
US61/618,862 | 2012-04-02 | ||
US61/618,911 | 2012-04-02 | ||
US61/618,866 | 2012-04-02 | ||
US61/618,896 | 2012-04-02 | ||
US61/618,953 | 2012-04-02 | ||
US61/618,922 | 2012-04-02 | ||
US61/618,878 | 2012-04-02 | ||
US61/618,957 | 2012-04-02 | ||
US61/618,868 | 2012-04-02 | ||
US61/618,885 | 2012-04-02 | ||
US61/618,870 | 2012-04-02 | ||
US61/618,873 | 2012-04-02 | ||
US201261648286P | 2012-05-17 | 2012-05-17 | |
US201261648244P | 2012-05-17 | 2012-05-17 | |
US61/648,286 | 2012-05-17 | ||
US61/648,244 | 2012-05-17 | ||
US201261668157P | 2012-07-05 | 2012-07-05 | |
US61/668,157 | 2012-07-05 | ||
US201261681720P | 2012-08-10 | 2012-08-10 | |
US201261681667P | 2012-08-10 | 2012-08-10 | |
US201261681687P | 2012-08-10 | 2012-08-10 | |
US201261681742P | 2012-08-10 | 2012-08-10 | |
US201261681645P | 2012-08-10 | 2012-08-10 | |
US201261681647P | 2012-08-10 | 2012-08-10 | |
US201261681712P | 2012-08-10 | 2012-08-10 | |
US201261681696P | 2012-08-10 | 2012-08-10 | |
US201261681654P | 2012-08-10 | 2012-08-10 | |
US201261681649P | 2012-08-10 | 2012-08-10 | |
US201261681648P | 2012-08-10 | 2012-08-10 | |
US201261681661P | 2012-08-10 | 2012-08-10 | |
US201261681704P | 2012-08-10 | 2012-08-10 | |
US201261681675P | 2012-08-10 | 2012-08-10 | |
US201261681658P | 2012-08-10 | 2012-08-10 | |
US201261681650P | 2012-08-10 | 2012-08-10 | |
US61/681,654 | 2012-08-10 | ||
US61/681,648 | 2012-08-10 | ||
US61/681,650 | 2012-08-10 | ||
US61/681,687 | 2012-08-10 | ||
US61/681,675 | 2012-08-10 | ||
US61/681,696 | 2012-08-10 | ||
US61/681,658 | 2012-08-10 | ||
US61/681,742 | 2012-08-10 | ||
US61/681,647 | 2012-08-10 | ||
US61/681,704 | 2012-08-10 | ||
US61/681,712 | 2012-08-10 | ||
US61/681,645 | 2012-08-10 | ||
US61/681,667 | 2012-08-10 | ||
US61/681,661 | 2012-08-10 | ||
US61/681,649 | 2012-08-10 | ||
US61/681,720 | 2012-08-10 | ||
US201261696381P | 2012-09-04 | 2012-09-04 | |
US61/696,381 | 2012-09-04 | ||
US201261709303P | 2012-10-03 | 2012-10-03 | |
US61/709,303 | 2012-10-03 | ||
US201261712490P | 2012-10-11 | 2012-10-11 | |
US61/712,490 | 2012-10-11 | ||
US201261737213P | 2012-12-14 | 2012-12-14 | |
US201261737174P | 2012-12-14 | 2012-12-14 | |
US201261737155P | 2012-12-14 | 2012-12-14 | |
US201261737203P | 2012-12-14 | 2012-12-14 | |
US201261737130P | 2012-12-14 | 2012-12-14 | |
US201261737168P | 2012-12-14 | 2012-12-14 | |
US201261737160P | 2012-12-14 | 2012-12-14 | |
US201261737152P | 2012-12-14 | 2012-12-14 | |
US201261737135P | 2012-12-14 | 2012-12-14 | |
US201261737139P | 2012-12-14 | 2012-12-14 | |
US201261737147P | 2012-12-14 | 2012-12-14 | |
US201261737184P | 2012-12-14 | 2012-12-14 | |
US201261737191P | 2012-12-14 | 2012-12-14 | |
US201261737134P | 2012-12-14 | 2012-12-14 | |
US61/737,139 | 2012-12-14 | ||
US61/737,152 | 2012-12-14 | ||
US61/737,203 | 2012-12-14 | ||
US61/737,174 | 2012-12-14 | ||
US61/737,184 | 2012-12-14 | ||
US61/737,160 | 2012-12-14 | ||
US61/737,155 | 2012-12-14 | ||
US61/737,134 | 2012-12-14 | ||
US61/737,191 | 2012-12-14 | ||
US61/737,130 | 2012-12-14 | ||
US61/737,135 | 2012-12-14 | ||
US61/737,147 | 2012-12-14 | ||
US61/737,213 | 2012-12-14 | ||
US61/737,168 | 2012-12-14 | ||
PCT/US2013/030062 WO2013151666A2 (en) | 2012-04-02 | 2013-03-09 | Modified polynucleotides for the production of biologics and proteins associated with human disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017018370A Division JP6430552B2 (ja) | 2012-04-02 | 2017-02-03 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015518705A true JP2015518705A (ja) | 2015-07-06 |
Family
ID=49301149
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015504565A Pending JP2015518705A (ja) | 2012-04-02 | 2013-03-09 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2017018370A Active JP6430552B2 (ja) | 2012-04-02 | 2017-02-03 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2018204593A Active JP6921797B2 (ja) | 2012-04-02 | 2018-10-31 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2021122947A Pending JP2021192606A (ja) | 2012-04-02 | 2021-07-28 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2023114173A Pending JP2023130471A (ja) | 2012-04-02 | 2023-07-12 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017018370A Active JP6430552B2 (ja) | 2012-04-02 | 2017-02-03 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2018204593A Active JP6921797B2 (ja) | 2012-04-02 | 2018-10-31 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2021122947A Pending JP2021192606A (ja) | 2012-04-02 | 2021-07-28 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
JP2023114173A Pending JP2023130471A (ja) | 2012-04-02 | 2023-07-12 | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
Country Status (6)
Country | Link |
---|---|
JP (5) | JP2015518705A (xx) |
CN (2) | CN108949772A (xx) |
AU (4) | AU2013243949A1 (xx) |
CA (1) | CA2868391A1 (xx) |
HK (1) | HK1206612A1 (xx) |
WO (1) | WO2013151666A2 (xx) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6231252B1 (ja) * | 2016-07-08 | 2017-11-15 | 花王株式会社 | 核酸試料の調製方法 |
WO2018008319A1 (ja) * | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
JP2019500430A (ja) * | 2015-12-17 | 2019-01-10 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | メチルマロニルCoAムターゼをコードするポリヌクレオチド |
JP2019533708A (ja) * | 2016-11-10 | 2019-11-21 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
JP2020061955A (ja) * | 2018-10-16 | 2020-04-23 | 公立大学法人横浜市立大学 | 新生児期〜小児期発症の脳小血管病又はその保因者の検出方法 |
JP2021504343A (ja) * | 2017-11-22 | 2021-02-15 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
JP2021052808A (ja) * | 2013-03-14 | 2021-04-08 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNAによってコードされる抗体を送達するための方法及び組成物 |
JP2021523916A (ja) * | 2018-05-15 | 2021-09-09 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
Families Citing this family (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
DK2591114T3 (en) | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK4066857T3 (da) | 2010-08-31 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
LT3590949T (lt) | 2010-10-01 | 2022-07-25 | Modernatx, Inc. | Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas |
CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
AU2012267531B2 (en) | 2011-06-08 | 2017-06-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
MX354267B (es) | 2011-10-03 | 2018-02-21 | Moderna Therapeutics Inc Star | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
CA2868996A1 (en) * | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US20150315541A1 (en) * | 2012-12-13 | 2015-11-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
PL2934567T3 (pl) | 2012-12-21 | 2018-10-31 | Sanofi | Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon |
EP2946014A2 (en) * | 2013-01-17 | 2015-11-25 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
IL290953B2 (en) | 2013-03-14 | 2024-01-01 | Ethris Gmbh | CFTR mRNA Assemblies and Related Methods and Uses |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014143884A2 (en) * | 2013-03-15 | 2014-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic methylmalonyl-coa mutase transgene for the treatment of mut class methylmalonic acidemia (mma) |
EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
ES2795249T3 (es) | 2013-03-15 | 2020-11-23 | Translate Bio Inc | Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas |
EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
US9944918B2 (en) | 2013-03-15 | 2018-04-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA) |
WO2015006747A2 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use. |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3052106A4 (en) * | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EA201690675A1 (ru) * | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
EP3058082A4 (en) * | 2013-10-18 | 2017-04-26 | ModernaTX, Inc. | Compositions and methods for tolerizing cellular systems |
CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
KR102096796B1 (ko) | 2013-10-22 | 2020-05-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 전달을 위한 지질 제형 |
US9522176B2 (en) | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3053585A1 (en) * | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
EP3092250A4 (en) | 2014-01-08 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
HUE051311T2 (hu) | 2014-03-09 | 2021-03-01 | Univ Pennsylvania | Ornitin transzkarbamiláz (TC) deficiencia kezelésében alkalmas készítmények |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
SG11201608798YA (en) | 2014-04-23 | 2016-11-29 | Modernatx Inc | Nucleic acid vaccines |
WO2015164743A2 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
EA201691696A1 (ru) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
WO2015162302A2 (en) | 2014-04-25 | 2015-10-29 | Genethon | Treatment of hyperbilirubinemia |
CA2949106C (en) | 2014-05-30 | 2023-10-24 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
PE20171238A1 (es) | 2014-06-24 | 2017-08-24 | Shire Human Genetic Therapies | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos |
CA2953265C (en) | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
EP4159741A1 (en) | 2014-07-16 | 2023-04-05 | ModernaTX, Inc. | Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage |
US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
AU2015323944B2 (en) | 2014-10-01 | 2018-11-29 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-21 as an adjuvant |
EP4324473A3 (en) * | 2014-11-10 | 2024-05-29 | ModernaTX, Inc. | Multiparametric nucleic acid optimization |
US9943595B2 (en) | 2014-12-05 | 2018-04-17 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
PT3233129T (pt) * | 2014-12-17 | 2020-04-15 | Fundacion Para La Investig Medica Aplicada | Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições |
DK3233130T3 (da) | 2014-12-17 | 2021-06-21 | Fundacion Para La Investig Medica Aplicada | Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom |
JP6895892B2 (ja) | 2015-03-19 | 2021-06-30 | トランスレイト バイオ, インコーポレイテッド | ポンペ病のmRNA治療 |
UA124187C2 (uk) | 2015-04-24 | 2021-08-04 | Феррінг Б.В. | Спосіб отримання гонадотропіну |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
EP3101125A1 (en) * | 2015-06-05 | 2016-12-07 | Laboratorios Del Dr. Esteve, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
US10808242B2 (en) | 2015-08-28 | 2020-10-20 | Biontech Rna Pharmaceuticals Gmbh | Method for reducing immunogenicity of RNA |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
CN114686548A (zh) | 2015-10-14 | 2022-07-01 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
DK3365438T3 (da) * | 2015-10-21 | 2021-07-12 | Us Health | Codon-optimeret reduceret-størrelse atp7a cdna og anvendelser ved behandling af kobbertransportlidelser |
AU2016342045A1 (en) * | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN108430456B (zh) * | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
WO2017083764A1 (en) * | 2015-11-13 | 2017-05-18 | Baxalta Incorporated | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
TWI695069B (zh) * | 2015-11-13 | 2020-06-01 | 美商百克莎塔股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體之病毒載體 |
US20190307857A1 (en) * | 2015-12-09 | 2019-10-10 | Modernatx, Inc. | MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF |
JP7061067B2 (ja) | 2015-12-14 | 2022-04-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | クリグラー・ナジャー症候群の処置のための組成物 |
ES2919552T3 (es) | 2015-12-23 | 2022-07-27 | Modernatx Inc | Procedimientos de utilización de polinucleotidos codificadores de ligando ox40 |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
EP3429613A4 (en) * | 2016-03-14 | 2020-01-15 | Kiromic, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER |
KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
MA45053A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique |
US20190390181A1 (en) * | 2016-05-18 | 2019-12-26 | Modernatx, Inc. | Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia |
EP3458105B1 (en) * | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
WO2017201340A2 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
CA3024625A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
EP3842530A1 (en) * | 2016-06-13 | 2021-06-30 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
WO2018009838A1 (en) | 2016-07-07 | 2018-01-11 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
EP3293259A1 (en) * | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
EP3565605A1 (en) | 2017-01-03 | 2019-11-13 | ethris GmbH | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
CA3049661A1 (en) | 2017-01-11 | 2018-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | R-spondin (rspo) surrogate molecules |
WO2018140821A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
US20190351039A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
AU2018224387A1 (en) | 2017-02-22 | 2019-09-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
MA47603A (fr) | 2017-02-27 | 2020-01-01 | Translate Bio Inc | Nouvel arnm cftr à codons optimisés |
AU2018268859A1 (en) | 2017-05-16 | 2019-12-12 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR |
CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
WO2018222925A1 (en) * | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for phenylketonuria |
US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
MA49395A (fr) | 2017-06-14 | 2020-04-22 | Modernatx Inc | Polynucléotides codant pour le facteur viii de coagulation |
EP3638215A4 (en) * | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
AU2018308684A1 (en) * | 2017-07-27 | 2020-02-06 | Eukarys | New chimeric enzymes and their applications |
CN109423514A (zh) * | 2017-08-24 | 2019-03-05 | 上海市计划生育科学研究所 | 反复自然流产相关微小rna及其应用 |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
WO2019048631A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE |
EP3714047A2 (en) | 2017-11-22 | 2020-09-30 | ModernaTX, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
CA3079543A1 (en) * | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
JP2021508490A (ja) | 2017-12-15 | 2021-03-11 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチドを含む組成物及びその使用 |
AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
IT201800003279A1 (it) * | 2018-03-05 | 2019-09-05 | Consiglio Nazionale Ricerche | Peptide neurotrofico per il trattamento terapeutico di patologie neurodegenerative e/o infiammatorie. |
EP3762495A4 (en) * | 2018-03-07 | 2021-12-22 | Icahn School of Medicine at Mount Sinai | SPHINGOLIPID-METABOLIZING PROTEINS CODING FOR MODRNA |
US11566246B2 (en) | 2018-04-12 | 2023-01-31 | Mina Therapeutics Limited | SIRT1-saRNA compositions and methods of use |
EP3781683A4 (en) * | 2018-04-18 | 2022-02-16 | Ligandal, Inc. | METHODS AND COMPOSITIONS FOR GENOME EDITING |
KR20210021310A (ko) * | 2018-05-16 | 2021-02-25 | 스파크 테라퓨틱스, 인코포레이티드 | 코돈-최적화된 산 알파-글루코시다제 발현 카세트 및 이를 사용하는 방법 |
KR20210027389A (ko) | 2018-06-28 | 2021-03-10 | 크리스퍼 테라퓨틱스 아게 | 공여자 폴리뉴클레오티드의 삽입에 의한 게놈 편집을 위한 조성물 및 방법 |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
EP3846776A1 (en) | 2018-09-02 | 2021-07-14 | ModernaTX, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
US20220243182A1 (en) | 2018-09-13 | 2022-08-04 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
JP2022500436A (ja) | 2018-09-13 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド |
MA53615A (fr) | 2018-09-14 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar |
MA53734A (fr) | 2018-09-27 | 2021-08-04 | Modernatx Inc | Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
CA3114892A1 (en) | 2018-10-04 | 2020-04-09 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed rna |
WO2020083979A1 (en) | 2018-10-23 | 2020-04-30 | Glycardial Diagnostics, S.L. | Antibodies specific for glycosylated apoj and uses thereof |
BR112021008434A2 (pt) * | 2018-11-07 | 2021-09-28 | Vivet Therapeutics | Transgene abcb11 otimizado por códon para o tratamento de colestase intra-hepática familiar progressiva tipo 2 (pfic2) |
TW202039546A (zh) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
CN109734791B (zh) * | 2019-01-17 | 2022-07-12 | 武汉明德生物科技股份有限公司 | 人nf186抗原、人nf186抗体检测试剂盒及其制备方法与应用 |
US20230123802A1 (en) * | 2019-03-27 | 2023-04-20 | Sigilon Therapeutics, Inc. | Compositions, devices, and methods for factor vii therapy |
WO2020208361A1 (en) | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
JP2022532078A (ja) | 2019-05-08 | 2022-07-13 | アストラゼネカ アクチボラグ | 皮膚及び創傷のための組成物並びにその使用の方法 |
MX2021014293A (es) * | 2019-05-24 | 2022-03-11 | Ultragenyx Pharmaceutical Inc | Composiciones y métodos para el tratamiento contra hemocromatosis. |
JP2022545101A (ja) | 2019-08-19 | 2022-10-25 | ミナ セラピューティクス リミテッド | オリゴヌクレオチドコンジュゲート組成物および使用方法 |
MX2022002763A (es) | 2019-09-06 | 2022-04-06 | Crispr Therapeutics Ag | Linfocitos t modificados por ingenieria genetica que tienen persistencia mejorada en cultivo. |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB201918586D0 (en) | 2019-12-17 | 2020-01-29 | Patterson James | Engineered platelets for targeted delivery of a therapeutic agent |
CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
CN112111524B (zh) * | 2020-01-10 | 2024-02-27 | 深圳瑞吉生物科技有限公司 | mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用 |
EP4107176A4 (en) * | 2020-02-20 | 2024-03-20 | Gritstone Bio Inc | ANTIGEN-BINDING PROTEINS TARGETING THE SHARED ANTIGEN KKLC-1 |
KR102462990B1 (ko) * | 2020-03-17 | 2022-11-07 | 에이비온 주식회사 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
JP2023524071A (ja) * | 2020-05-01 | 2023-06-08 | アークトゥラス・セラピューティクス・インコーポレイテッド | 嚢胞性線維症を治療するための核酸及び方法 |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CA3192280A1 (en) | 2020-09-23 | 2022-03-31 | Mary-Lee Dequeant | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence |
IL302625A (en) | 2020-11-13 | 2023-07-01 | Modernatx Inc | Cystic fibrosis-encoding polynucleotides transmembrane conductance regulator for the treatment of cystic fibrosis |
US20220193134A1 (en) | 2020-12-23 | 2022-06-23 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
US11028379B1 (en) | 2021-01-27 | 2021-06-08 | New England Biolabs, Inc. | FCE mRNA capping enzyme compositions, methods and kits |
AU2021424650A1 (en) | 2021-01-27 | 2023-08-17 | New England Biolabs, Inc. | Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
CN113209124B (zh) * | 2021-02-24 | 2022-04-15 | 四川大学 | Dna四面体在制备预防和治疗1型糖尿病的药物中的用途 |
EP4305153A1 (en) | 2021-03-09 | 2024-01-17 | CRISPR Therapeutics AG | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
US20240175033A1 (en) | 2021-03-26 | 2024-05-30 | Mina Therapeutics Limited | TMEM173 saRNA Compositions and Methods of Use |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
GB202108585D0 (en) | 2021-06-16 | 2021-07-28 | Rockend Ltd | Methods and compositions |
WO2023288285A1 (en) * | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Polycistronic expression vectors |
CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
US20230128917A1 (en) | 2021-09-14 | 2023-04-27 | Crispr Therapeutics Ag | Genetically engineered immune cells having a disrupted cd83 gene |
TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
CA3235867A1 (en) | 2021-10-22 | 2023-04-27 | Munir MOSAHEB | Mrna vaccine composition |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023084399A1 (en) | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
WO2023107896A1 (en) * | 2021-12-06 | 2023-06-15 | Empirico Inc. | Treatment of fgg related diseases and disorders |
WO2023111913A1 (en) | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023119201A2 (en) | 2021-12-22 | 2023-06-29 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
EP4238988A1 (en) | 2022-03-01 | 2023-09-06 | Consejo Superior De Investigaciones Científicas | Antibodies against sars-cov-2 and uses thereof |
WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
CN114685586A (zh) * | 2022-03-05 | 2022-07-01 | 武汉瑞佶生物科技有限公司 | 一种mRNA-脂肪酸靶向化合物及其制备方法和应用 |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
WO2023177904A1 (en) | 2022-03-18 | 2023-09-21 | Modernatx, Inc. | Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications |
TW202403046A (zh) | 2022-03-21 | 2024-01-16 | 瑞士商Crispr治療公司 | 用於治療脂蛋白相關的疾病之方法及組成物 |
US20230303713A1 (en) | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
US20230331841A1 (en) | 2022-03-23 | 2023-10-19 | Crispr Therapeutics Ag | Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption |
WO2023196950A1 (en) | 2022-04-07 | 2023-10-12 | New England Biolabs, Inc. | Methods of higher fidelity rna synthesis |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
TW202400784A (zh) * | 2022-05-13 | 2024-01-01 | 大陸商上海瑞宏迪醫藥有限公司 | 包含utr的核酸構建體及其應用 |
WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
CN114632092B (zh) * | 2022-05-17 | 2022-08-23 | 北京第一生物化学药业有限公司 | 睾丸片在制备具有降糖活性的药物中的应用 |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US20240041757A1 (en) | 2022-06-17 | 2024-02-08 | Crispr Therapeutics Ag | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY |
WO2023248110A1 (en) | 2022-06-20 | 2023-12-28 | Crispr Therapeutics Ag | Base editing proteins and uses thereof |
WO2023248145A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Compositions and methods for treating human immunodeficiency virus |
WO2023248147A1 (en) | 2022-06-21 | 2023-12-28 | Crispr Therapeutics Ag | Methods and compositions for in vivo editing of stem cells |
WO2024003786A1 (en) | 2022-06-29 | 2024-01-04 | Crispr Therapeutics Ag | Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses |
WO2024023802A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
WO2024023804A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene |
WO2024023801A2 (en) | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene |
WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
WO2024062388A2 (en) | 2022-09-20 | 2024-03-28 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20 |
WO2024074142A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Polynucleotides for the treatment of disease associated with gcase deficiency |
US20240156949A1 (en) | 2022-10-28 | 2024-05-16 | Glaxosmithkline Biologicals Sa | Nucleic Acid Based Vaccine |
WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
CN117517658B (zh) * | 2023-11-14 | 2024-04-12 | 北京大学 | 检测组蛋白烟酰化修饰试剂的新用途 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007501615A (ja) * | 2003-08-08 | 2007-02-01 | (オーエスアイ)アイテツク・インコーポレーテツド | 5’−および3’−キャップド・アプタマーおよびそれらの使用 |
JP2008513513A (ja) * | 2004-09-21 | 2008-05-01 | アネシヴァ, インコーポレイテッド | ポリヌクレオチドの送達 |
WO2010054401A1 (en) * | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
WO2010144740A1 (en) * | 2009-06-10 | 2010-12-16 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
WO2011000107A1 (en) * | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2012019168A2 (en) * | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
JP2012505250A (ja) * | 2008-10-09 | 2012-03-01 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
WO2012031046A2 (en) * | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
JP2015504567A (ja) * | 2011-11-28 | 2015-02-12 | エクスパナージー,エルエルシー | エネルギーサーチエンジンの方法及びシステム |
JP2015504562A (ja) * | 2011-11-25 | 2015-02-12 | インターナショナル・ビジネス・マシーンズ・コーポレーションInternational Business Machines Corporation | 共有リソース・システム、リソースを割り振る方法、およびコンピュータ・プログラム製品(共有リソースをプロビジョニングするための、コストを意識したテンプレート選択のためのシステム、方法、およびプログラム製品) |
JP2015504563A (ja) * | 2011-11-23 | 2015-02-12 | プロテウス デジタル ヘルス, インコーポレイテッド | マインドフルネス技法に基づいて行動変容を促進するデバイス、システム、および方法 |
JP2015504564A (ja) * | 2011-11-29 | 2015-02-12 | アリババ・グループ・ホールディング・リミテッドAlibaba Group Holding Limited | 属性データ区間の分類 |
JP2015504568A (ja) * | 2011-10-06 | 2015-02-12 | ネグゼオン・リミテッドNexeon Ltd | エッチングされたシリコン構造、エッチングされたシリコン構造を形成する方法及びそれらの使用 |
JP2015504569A (ja) * | 2011-10-13 | 2015-02-12 | フレクスコン カンパニー インク | 容量結合された医用電極において過充電保護をするためのシステムおよび方法 |
JP2015504566A (ja) * | 2011-12-01 | 2015-02-12 | ローベルト ボッシュ ゲゼルシャフト ミット ベシュレンクテル ハフツング | バスデータパケットからのユーザデータを様々なセンサ伝送装置へと割り当てる方法、センサ伝送装置、バス制御装置、およびプログラムが記録された担体 |
Family Cites Families (317)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5221732A (en) | 1988-12-06 | 1993-06-22 | The United States Of America As Represented By The Department Of Health And Human Services | Antimicrobial magainin modified peptides |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
EP0497875B1 (en) | 1989-10-24 | 2000-03-22 | Isis Pharmaceuticals, Inc. | 2' modified oligonucleotides |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US6783931B1 (en) | 1990-01-11 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US7037646B1 (en) | 1990-01-11 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
CA2042448A1 (en) | 1990-06-05 | 1991-12-06 | Jonathan P. Duvick | Antimicrobial peptides and plant disease resistance based thereon |
US5447914A (en) | 1990-06-21 | 1995-09-05 | Emory University | Antimicrobial peptides |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
DE69132510T2 (de) | 1990-11-08 | 2001-05-03 | Hybridon Inc | Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden |
AU648140B2 (en) | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5607914A (en) | 1993-01-13 | 1997-03-04 | Pioneer Hi-Bred International, Inc. | Synthetic antimicrobial peptides |
US5459235A (en) | 1993-03-19 | 1995-10-17 | The Regents Of The University Of California | Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils |
WO1994022864A1 (en) | 1993-03-30 | 1994-10-13 | Sterling Winthrop Inc. | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
US6294664B1 (en) | 1993-07-29 | 2001-09-25 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5550109A (en) | 1994-05-24 | 1996-08-27 | Magainin Pharmaceuticals Inc. | Inducible defensin peptide from mammalian epithelia |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6057291A (en) | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
US5734015A (en) | 1995-06-19 | 1998-03-31 | Magainin Pharmaceuticals Inc. | Family of linear antimicrobial peptides from hagfish intestine |
US6191254B1 (en) | 1995-08-23 | 2001-02-20 | University Of British Columbia | Antimicrobial cationic peptides |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
CN1145695C (zh) | 1995-12-13 | 2004-04-14 | 辛甄塔有限公司 | 抗真菌蛋白 |
US5714577A (en) | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
US5773696A (en) | 1996-03-29 | 1998-06-30 | Monsanto Company | Antifungal polypeptide and methods for controlling plant pathogenic fungi |
US5856127A (en) | 1996-07-26 | 1999-01-05 | The Research Foundation Of State University Of New York | Antimicrobial peptides |
JP2001502891A (ja) | 1996-08-22 | 2001-03-06 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | デフェンシンを使用するための組成物および方法 |
US6121436A (en) | 1996-12-13 | 2000-09-19 | Monsanto Company | Antifungal polypeptide and methods for controlling plant pathogenic fungi |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US5998374A (en) | 1997-02-28 | 1999-12-07 | The Regents Of University Of California | Clavaspirins |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
NL1006164C2 (nl) | 1997-05-29 | 1998-12-01 | Univ Leiden | Antimicrobiële peptiden. |
FR2766191B1 (fr) | 1997-07-21 | 2000-11-10 | Ifremer | Peptides anti-microbiens de crustaces |
US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
WO1999006440A1 (en) | 1997-07-31 | 1999-02-11 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome |
US6576755B1 (en) | 1997-09-10 | 2003-06-10 | Zymogenetics, Inc. | Beta-defensins |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
WO1999014346A2 (en) | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | SENSE mRNA THERAPY |
EP1015486A2 (en) | 1997-09-25 | 2000-07-05 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Isolated and recombinant antimicrobial peptides thrombocidin-1 (tc-1) and thrombocidin-2 (tc-2) or variants thereof |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
US7655777B2 (en) * | 1997-11-24 | 2010-02-02 | Monsanto Technology Llc | Nucleic acid molecules associated with the tocopherol pathway |
US6517869B1 (en) | 1997-12-12 | 2003-02-11 | Expression Genetics, Inc. | Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake |
AU1819499A (en) | 1997-12-12 | 1999-06-28 | Samyang Corporation | Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
JP2002500201A (ja) | 1998-01-05 | 2002-01-08 | ユニバーシティ オブ ワシントン | 膜破壊剤を使用する増強された輸送 |
NL1008139C2 (nl) | 1998-01-27 | 1999-07-28 | Stichting Tech Wetenschapp | Antimicrobiële peptiden. |
CA2320429C (en) | 1998-02-18 | 2011-04-19 | Harbor-Ucla Research And Education Institute | Antimicrobial peptides and derived metapeptides |
EP0953641A3 (en) * | 1998-03-26 | 2002-03-13 | Pfizer Products Inc. | Polynucleotide molecules encoding neospora proteins |
JPH11326617A (ja) * | 1998-05-13 | 1999-11-26 | Olympus Optical Co Ltd | 回折光学素子を含む光学系及びその設計方法 |
CA2329147A1 (en) | 1998-05-20 | 1999-11-25 | Feng Liu | A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier |
WO2000002950A1 (en) | 1998-07-13 | 2000-01-20 | Expression Genetics, Inc. | Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
US6476189B1 (en) | 1998-08-12 | 2002-11-05 | National Institute Of Agrobiological Sciences | Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient |
US6288212B1 (en) | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
US6107460A (en) | 1999-03-01 | 2000-08-22 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use thereof |
US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
US7244710B2 (en) | 2002-05-21 | 2007-07-17 | Zengen, Inc. | Treatment of ophthalmic infections using antimicrobial peptides |
KR100782896B1 (ko) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-리보-lna 유사체 |
CN1351611A (zh) | 1999-05-17 | 2002-05-29 | 康久化学公司 | 病毒感染的长效融合肽抑制剂 |
FR2796072B1 (fr) | 1999-07-08 | 2003-09-19 | Centre Nat Rech Scient | Peptides anti-microbiens de mollusques |
CA2311201A1 (en) | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
US7071293B1 (en) | 1999-08-18 | 2006-07-04 | The University Of Iowa Research Foundation | Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt |
EP1101771A1 (en) | 1999-11-15 | 2001-05-23 | Korea Kumho Petrochemical Co. Ltd. | Pathogen-induced genes from Capsicum annuum |
US6573361B1 (en) | 1999-12-06 | 2003-06-03 | Monsanto Technology Llc | Antifungal proteins and methods for their use |
US6794490B2 (en) | 1999-12-15 | 2004-09-21 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
AU2764801A (en) | 2000-01-07 | 2001-07-24 | University Of Washington | Enhanced transport of agents using membrane disruptive agents |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
CA2335389A1 (en) | 2000-03-01 | 2001-09-01 | Message Pharmaceuticals, Inc. | Novel bacterial rnase p proteins and their use in identifying antibacterial compounds |
US6337317B1 (en) | 2000-06-27 | 2002-01-08 | The University Of British Columbia | Antimicrobial peptides and methods of use thereof |
US6492328B2 (en) | 2000-06-28 | 2002-12-10 | The University Of Iowa Research Foundation | Novispirins: antimicrobial peptides |
AU2001279073B2 (en) | 2000-07-28 | 2006-08-24 | Christopher J. Murphy | Transplant media |
US6727066B2 (en) | 2000-07-28 | 2004-04-27 | Incyte Corporation | Genes expressed in treated human C3A liver cell cultures |
US6875907B2 (en) | 2000-09-13 | 2005-04-05 | Pioneer Hi-Bred International, Inc. | Antimicrobial peptides and methods of use |
US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
DK1334109T3 (da) | 2000-10-04 | 2006-10-09 | Santaris Pharma As | Forbedret syntese af purin-blokerede nukleinsyre-analoger |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
GB0026924D0 (en) | 2000-11-03 | 2000-12-20 | Univ Cambridge Tech | Antibacterial agents |
US6835713B2 (en) | 2001-02-16 | 2004-12-28 | University Of Pittsburgh | Virus derived antimicrobial peptides |
US6887847B2 (en) | 2001-02-16 | 2005-05-03 | University Of Pittsburgh | Virus derived antimicrobial peptides |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
US7314858B2 (en) | 2001-04-18 | 2008-01-01 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
US6872705B2 (en) | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
WO2003014078A2 (en) | 2001-08-08 | 2003-02-20 | The Research Foundation Of The State University Of New York | Muc7d1 peptides as antifungal and antibacterial agents |
US6743598B2 (en) | 2001-08-10 | 2004-06-01 | Mycologics, Inc. | Methods for the identification of fungal glucose utilization inhibitors and antifungal agents |
US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
WO2003024407A2 (en) | 2001-09-21 | 2003-03-27 | Message Pharmaceuticals, Inc. | Inhibitors of rnase p proteins as antibacterial compounds |
AU2002347035B2 (en) | 2001-09-28 | 2008-04-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Micro-RNA molecules |
US20060051424A1 (en) | 2001-10-03 | 2006-03-09 | Johns Hopkins University | Compositions of oral gene therapy and methods of using same |
US6478825B1 (en) | 2001-11-28 | 2002-11-12 | Osteotech, Inc. | Implant, method of making same and use of the implant for the treatment of bone defects |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
MXPA04004919A (es) | 2001-12-21 | 2004-08-11 | Alcon Inc | Uso de nanoparticulas inorganicas sinteticas como vehiculos para farmacos oftalmicos y oticos. |
US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
US7374930B2 (en) | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
CA2493808A1 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
WO2004067728A2 (en) | 2003-01-17 | 2004-08-12 | Ptc Therapeutics | Methods and systems for the identification of rna regulatory sequences and compounds that modulate their function |
US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
EP1604011A4 (en) | 2003-01-21 | 2009-12-09 | Ptc Therapeutics Inc | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME |
US7091185B2 (en) | 2003-02-24 | 2006-08-15 | Dow Global Technologies Inc. | Periodic antimicrobial peptides |
GB0316089D0 (en) | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
KR100992646B1 (ko) | 2003-07-09 | 2010-11-05 | 제이에스알 가부시끼가이샤 | 파장판 |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
JP2005179268A (ja) | 2003-12-19 | 2005-07-07 | Gc Corp | 口腔用組成物 |
US7927873B2 (en) | 2003-12-19 | 2011-04-19 | University Of Cincinnati | Polyamides for nucleic acid delivery |
US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
US20050232981A1 (en) | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
US7527947B2 (en) | 2004-06-14 | 2009-05-05 | Novozymes A/S | Signal peptide for producing a polypeptide |
DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
AU2005295727A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
WO2006065480A2 (en) | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
EP1856179B1 (en) | 2004-12-10 | 2013-05-15 | Kala Pharmaceuticals, Inc. | Functionalized poly (ether-anhydride) block copolymers |
WO2006071903A2 (en) | 2004-12-28 | 2006-07-06 | Ptc Therapeutics, Inc. | Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions |
US8192718B1 (en) | 2005-01-04 | 2012-06-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8187570B1 (en) | 2005-01-04 | 2012-05-29 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
ATE440117T1 (de) | 2005-04-01 | 2009-09-15 | Intezyne Technologies Inc | Polymermicellen für die arzneistoffzufuhr |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
CA2611985C (en) | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
WO2007005645A2 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
SI3611266T1 (sl) | 2005-08-23 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
US8603457B2 (en) | 2005-12-02 | 2013-12-10 | University Of Rochester | Nonsense suppression and genetic codon alteration by targeted modification |
WO2007082304A2 (en) | 2006-01-12 | 2007-07-19 | Massachusetts Institute Of Technology | Biodegradable elastomers |
JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ, インコーポレーテッド | 6−修飾された二環式核酸類似体 |
US20100215580A1 (en) | 2006-09-08 | 2010-08-26 | The Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
AU2007333528B2 (en) | 2006-10-05 | 2013-10-17 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
EP2104739B1 (en) | 2006-12-21 | 2013-06-19 | Novozymes Inc. | Modified messenger rna stabilizing sequences for expressing genes in bacterial cells |
CA2673029C (en) | 2006-12-22 | 2017-03-28 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
EP2173872B1 (en) | 2007-06-29 | 2014-04-02 | CellScript, Inc. | Copy dna and sense rna |
US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
JP5514727B2 (ja) | 2007-09-26 | 2014-06-04 | イントレキソン コーポレーション | 合成5’utr、発現ベクター、および導入遺伝子の発現を増加させる方法 |
SI2644192T1 (sl) | 2007-09-28 | 2017-08-31 | Pfizer Inc. | Ciljanje rakavih celic z uporabo nanodelcev |
CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
WO2009108891A2 (en) | 2008-02-29 | 2009-09-03 | Egen, Inc. | Modified poloxamers for gene expression and associated methods |
CN102027043A (zh) | 2008-03-14 | 2011-04-20 | 艾根股份有限公司 | 生物可降解的交联支链聚(亚烷基亚胺) |
WO2009127060A1 (en) * | 2008-04-15 | 2009-10-22 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
WO2010005723A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
DK2285350T3 (en) | 2008-06-16 | 2017-12-11 | Pfizer | PROCEDURES FOR THE PREPARATION OF DIBLOCK COPOLYMERS FUNCTIONALIZED WITH TARGETING AGENT FOR USE IN THE MANUFACTURE OF THERAPEUTIC NANOPARTICLES |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
WO2010001381A1 (en) | 2008-06-30 | 2010-01-07 | Association For Public Health Services | Air quality monitor |
US20100009424A1 (en) | 2008-07-14 | 2010-01-14 | Natasha Forde | Sonoporation systems and methods |
WO2010021865A1 (en) | 2008-08-18 | 2010-02-25 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
US8669085B2 (en) | 2009-02-05 | 2014-03-11 | Ut-Battelle, Llc | Transformation of gram positive bacteria by sonoporation |
JP5735927B2 (ja) | 2009-02-24 | 2015-06-17 | ザ スクリプス リサーチ インスティテュート | タンパク質生産の増強のためのmRNAの一次構造の再操作 |
JP5596712B2 (ja) | 2009-03-12 | 2014-09-24 | イリノイ トゥール ワークス インコーポレイティド | 給油ミス防止装置 |
AU2010226434A1 (en) | 2009-03-20 | 2011-10-13 | Egen, Inc. | Polyamine derivatives |
KR101702154B1 (ko) | 2009-03-24 | 2017-02-03 | 유니버시티 오브 시카고 | 반응을 수행하기 위한 장치 |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
MX2011011134A (es) | 2009-04-21 | 2012-01-31 | Selecta Biosciences Inc | Agentes inmunonanoterapeuticos que proporcionan una respuesta sesgada hacia th1. |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
NZ711583A (en) | 2009-05-05 | 2017-03-31 | Arbutus Biopharma Corp | Lipid compositions |
CN107033339A (zh) | 2009-05-27 | 2017-08-11 | 西莱克塔生物科技公司 | 免疫调节剂‑聚合物化合物 |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
CN102473288A (zh) | 2009-07-30 | 2012-05-23 | 皇家飞利浦电子股份有限公司 | 分布式图像重定向 |
AU2010278309B2 (en) | 2009-07-31 | 2013-10-31 | Ethris Gmbh | RNA with a combination of unmodified and modified nucleotides for protein expression |
JP5520376B2 (ja) | 2009-08-01 | 2014-06-11 | エフ.ホフマン−ラ ロシュ アーゲー | 改善された細菌(モリクテス綱)混入の検出 |
EP2467357B1 (en) | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
US20120253032A1 (en) | 2009-10-08 | 2012-10-04 | Merck Sharp & Dohme Corporation | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
WO2011060250A1 (en) | 2009-11-13 | 2011-05-19 | Bend Research, Inc. | Cationic dextran polymer derivatives |
WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
SI3112467T1 (en) | 2009-12-07 | 2018-06-29 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
CN102811743B (zh) | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
WO2011084521A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
JP6175237B2 (ja) | 2009-12-15 | 2017-08-02 | ファイザー・インク | コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法 |
ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
KR101762466B1 (ko) | 2009-12-23 | 2017-07-27 | 노파르티스 아게 | 지질, 지질 조성물 및 이의 사용 방법 |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
US9670487B2 (en) * | 2010-01-22 | 2017-06-06 | Sirna Therapeutics, Inc. | Cationic lipids for oligonucleotide delivery |
JP5988435B2 (ja) | 2010-01-24 | 2016-09-07 | ノバルティス アーゲー | 放射線照射された生分解性微粒子 |
CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
EP2547345A1 (en) | 2010-03-18 | 2013-01-23 | Merck Sharp & Dohme Corp. | Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides |
US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
EP3391877A1 (en) | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
CA2796464C (en) | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
CN102917731A (zh) | 2010-05-26 | 2013-02-06 | 西莱克塔生物科技公司 | 多价的合成纳米载体疫苗 |
JP5957646B2 (ja) | 2010-06-04 | 2016-07-27 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | オリゴヌクレオチド送達のための新規な低分子量カチオン性脂質 |
KR101130137B1 (ko) | 2010-07-02 | 2012-03-28 | 연세대학교 산학협력단 | 발광다이오드 모듈 |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
EP4005592B1 (en) | 2010-07-06 | 2022-10-12 | GlaxoSmithKline Biologicals S.A. | Virion-like delivery particles for self-replicating rna molecules |
GB2495418B (en) | 2010-07-28 | 2017-05-24 | Murata Manufacturing Co | Antenna apparatus and communication terminal instrument |
DE102010032758B4 (de) | 2010-07-29 | 2012-02-23 | Fujitsu Technology Solutions Intellectual Property Gmbh | Computersystem, Verfahren zum Programmieren einer Echtzeituhr und Computerprogrammprodukt |
JP5948327B2 (ja) | 2010-07-30 | 2016-07-06 | キュアヴァック アーゲー | トランスフェクションおよび免疫刺激のためのジスルフィド架橋されたカチオン性成分との核酸の複合体形成 |
WO2012016269A1 (en) | 2010-08-02 | 2012-02-09 | Curtin University Of Technology | Determining location of, and imaging, a subsurface boundary |
US8829329B2 (en) | 2010-08-18 | 2014-09-09 | International Business Machines Corporation | Solar cell and battery 3D integration |
WO2012024629A1 (en) | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin |
DK4066857T3 (da) | 2010-08-31 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
HRP20230326T1 (hr) | 2010-08-31 | 2023-06-09 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
EP3943114A1 (en) | 2010-09-20 | 2022-01-26 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
JP2013545723A (ja) | 2010-09-30 | 2013-12-26 | メルク・シャープ・エンド・ドーム・コーポレイション | オリゴヌクレオチドの送達のための低分子量カチオン性脂質 |
WO2012051220A1 (en) | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
EA201390600A1 (ru) | 2010-10-22 | 2013-09-30 | Байнд Терапьютикс, Инк. | Терапевтические наночастицы с сополимерами с большим молекулярным весом |
AU2011323250B2 (en) | 2010-11-05 | 2015-11-19 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
EP2635265B1 (en) | 2010-11-05 | 2018-04-04 | Sirna Therapeutics, Inc. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
WO2012068187A1 (en) | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
US8901101B2 (en) | 2010-12-17 | 2014-12-02 | Sirna Therapeutics, Inc. | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
CA2862765A1 (en) | 2011-01-04 | 2012-07-12 | Brown University | Nanotubes as carriers of nucleic acids into cells |
CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
DE102011002640B4 (de) | 2011-01-13 | 2021-10-07 | Evonik Operations Gmbh | Verfahren zur Aufreinigung von Biphephos |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
WO2012109121A1 (en) | 2011-02-07 | 2012-08-16 | Purdue Research Foundation | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
EP2489371A1 (en) | 2011-02-18 | 2012-08-22 | Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria | Carrier peptides for drug delivery |
US20120237565A1 (en) | 2011-03-14 | 2012-09-20 | Intezyne Technologies, Incorporated | Pegylated polyplexes containing two or more different polymers for polynucleotide delivery |
WO2012125987A2 (en) | 2011-03-17 | 2012-09-20 | Massachusetts Institute Of Technology | Delivery system |
WO2012135010A2 (en) | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
WO2012129648A1 (en) | 2011-03-25 | 2012-10-04 | University Of Guelph | Enhancing protein expression of adeno-associated virus vectors |
CA2831471C (en) | 2011-03-31 | 2020-02-25 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
EP2691079B1 (en) | 2011-03-31 | 2020-06-24 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
US20120283503A1 (en) | 2011-04-29 | 2012-11-08 | The Johns Hopkins University | Nanoparticle loaded stem cells and their use in mri guided hyperthermia |
US20120301510A1 (en) | 2011-04-29 | 2012-11-29 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use |
WO2012150467A2 (en) | 2011-05-04 | 2012-11-08 | The University Of Nottingham | Novel polymers which resist bacterial attachment |
US9327029B2 (en) | 2011-05-05 | 2016-05-03 | Celacare Technologies, Llc | Antimicrobial silver hydrogel composition for the treatment of burns and wounds |
US20120302940A1 (en) | 2011-05-26 | 2012-11-29 | Jackson State University | Popcorn Shape Gold Nanoparticle For Targeted Diagnosis, Photothermal Treatment and In-Situ Monitoring Therapy Response for Cancer and Multiple Drug Resistance Bacteria |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
EP3354644A1 (en) | 2011-06-08 | 2018-08-01 | Translate Bio, Inc. | Cleavable lipids |
AU2012267531B2 (en) | 2011-06-08 | 2017-06-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
WO2013009736A2 (en) | 2011-07-10 | 2013-01-17 | President And Fellows Of Harvard College | Compositions and methods for self-assembly of polymers with complementary macroscopic and microscopic scale units |
WO2013012476A2 (en) | 2011-07-21 | 2013-01-24 | Arizona Chemical Company, Llc | Branched polyether-polyamide block copolymers and methods of making and using the same |
US20130039954A1 (en) | 2011-07-29 | 2013-02-14 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
EP2755986A4 (en) * | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS AND METHODS OF USE |
-
2013
- 2013-03-09 JP JP2015504565A patent/JP2015518705A/ja active Pending
- 2013-03-09 CN CN201810507242.8A patent/CN108949772A/zh active Pending
- 2013-03-09 WO PCT/US2013/030062 patent/WO2013151666A2/en active Application Filing
- 2013-03-09 CN CN201380028773.4A patent/CN104411338A/zh active Pending
- 2013-03-09 AU AU2013243949A patent/AU2013243949A1/en not_active Abandoned
- 2013-03-09 CA CA2868391A patent/CA2868391A1/en active Pending
-
2015
- 2015-07-28 HK HK15107193.3A patent/HK1206612A1/xx unknown
-
2017
- 2017-02-03 JP JP2017018370A patent/JP6430552B2/ja active Active
-
2018
- 2018-01-19 AU AU2018200374A patent/AU2018200374B2/en active Active
- 2018-10-31 JP JP2018204593A patent/JP6921797B2/ja active Active
-
2021
- 2021-01-28 AU AU2021200507A patent/AU2021200507A1/en not_active Abandoned
- 2021-07-28 JP JP2021122947A patent/JP2021192606A/ja active Pending
-
2023
- 2023-07-12 JP JP2023114173A patent/JP2023130471A/ja active Pending
- 2023-08-08 AU AU2023214237A patent/AU2023214237A1/en active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007501615A (ja) * | 2003-08-08 | 2007-02-01 | (オーエスアイ)アイテツク・インコーポレーテツド | 5’−および3’−キャップド・アプタマーおよびそれらの使用 |
JP2008513513A (ja) * | 2004-09-21 | 2008-05-01 | アネシヴァ, インコーポレイテッド | ポリヌクレオチドの送達 |
JP2012505250A (ja) * | 2008-10-09 | 2012-03-01 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
WO2010054401A1 (en) * | 2008-11-10 | 2010-05-14 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
WO2010144740A1 (en) * | 2009-06-10 | 2010-12-16 | Alnylam Pharmaceuticals, Inc. | Improved lipid formulation |
WO2011000107A1 (en) * | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2012019168A2 (en) * | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012031046A2 (en) * | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
JP2015504568A (ja) * | 2011-10-06 | 2015-02-12 | ネグゼオン・リミテッドNexeon Ltd | エッチングされたシリコン構造、エッチングされたシリコン構造を形成する方法及びそれらの使用 |
JP2015504569A (ja) * | 2011-10-13 | 2015-02-12 | フレクスコン カンパニー インク | 容量結合された医用電極において過充電保護をするためのシステムおよび方法 |
JP2015504563A (ja) * | 2011-11-23 | 2015-02-12 | プロテウス デジタル ヘルス, インコーポレイテッド | マインドフルネス技法に基づいて行動変容を促進するデバイス、システム、および方法 |
JP2015504562A (ja) * | 2011-11-25 | 2015-02-12 | インターナショナル・ビジネス・マシーンズ・コーポレーションInternational Business Machines Corporation | 共有リソース・システム、リソースを割り振る方法、およびコンピュータ・プログラム製品(共有リソースをプロビジョニングするための、コストを意識したテンプレート選択のためのシステム、方法、およびプログラム製品) |
JP2015504567A (ja) * | 2011-11-28 | 2015-02-12 | エクスパナージー,エルエルシー | エネルギーサーチエンジンの方法及びシステム |
JP2015504564A (ja) * | 2011-11-29 | 2015-02-12 | アリババ・グループ・ホールディング・リミテッドAlibaba Group Holding Limited | 属性データ区間の分類 |
JP2015504566A (ja) * | 2011-12-01 | 2015-02-12 | ローベルト ボッシュ ゲゼルシャフト ミット ベシュレンクテル ハフツング | バスデータパケットからのユーザデータを様々なセンサ伝送装置へと割り当てる方法、センサ伝送装置、バス制御装置、およびプログラムが記録された担体 |
Non-Patent Citations (2)
Title |
---|
GENOME BIOL., 2002, VOL. 3, NO. 3, PP. 1-10, JPN6015047783, ISSN: 0003203543 * |
GENOMICS, 1997, VOL. 44, PP. 292-299, JPN6015047784, ISSN: 0003203544 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021052808A (ja) * | 2013-03-14 | 2021-04-08 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNAによってコードされる抗体を送達するための方法及び組成物 |
JP7256831B2 (ja) | 2013-03-14 | 2023-04-12 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | mRNAによってコードされる抗体を送達するための方法及び組成物 |
JP2019500430A (ja) * | 2015-12-17 | 2019-01-10 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | メチルマロニルCoAムターゼをコードするポリヌクレオチド |
JP7065036B2 (ja) | 2015-12-17 | 2022-05-11 | モダーナティエックス・インコーポレイテッド | メチルマロニルCoAムターゼをコードするポリヌクレオチド |
JP6231252B1 (ja) * | 2016-07-08 | 2017-11-15 | 花王株式会社 | 核酸試料の調製方法 |
WO2018008319A1 (ja) * | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
JP2018000206A (ja) * | 2016-07-08 | 2018-01-11 | 花王株式会社 | 核酸試料の調製方法 |
US11913061B2 (en) | 2016-07-08 | 2024-02-27 | Kao Corporation | Method for preparing nucleic acid sample |
JP2019533708A (ja) * | 2016-11-10 | 2019-11-21 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
JP2021504343A (ja) * | 2017-11-22 | 2021-02-15 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
JP7423522B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
US11859215B2 (en) | 2017-11-22 | 2024-01-02 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
JP2021523916A (ja) * | 2018-05-15 | 2021-09-09 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
JP7448488B2 (ja) | 2018-05-15 | 2024-03-12 | トランスレイト バイオ, インコーポレイテッド | メッセンジャーrnaの皮下送達 |
JP7301326B2 (ja) | 2018-10-16 | 2023-07-03 | 公立大学法人横浜市立大学 | 新生児期~小児期発症の脳小血管病又はその保因者の検出方法 |
JP2020061955A (ja) * | 2018-10-16 | 2020-04-23 | 公立大学法人横浜市立大学 | 新生児期〜小児期発症の脳小血管病又はその保因者の検出方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2013243949A1 (en) | 2014-10-30 |
AU2018200374A1 (en) | 2018-03-22 |
CA2868391A1 (en) | 2013-10-10 |
JP2019030327A (ja) | 2019-02-28 |
JP2021192606A (ja) | 2021-12-23 |
WO2013151666A3 (en) | 2014-01-09 |
AU2021200507A1 (en) | 2021-04-01 |
WO2013151666A2 (en) | 2013-10-10 |
JP6921797B2 (ja) | 2021-08-18 |
JP2023130471A (ja) | 2023-09-20 |
AU2018200374B2 (en) | 2020-11-19 |
AU2023214237A1 (en) | 2023-08-31 |
JP6430552B2 (ja) | 2018-11-28 |
CN108949772A (zh) | 2018-12-07 |
CN104411338A (zh) | 2015-03-11 |
JP2017121244A (ja) | 2017-07-13 |
HK1206612A1 (en) | 2016-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6430552B2 (ja) | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド | |
JP6946384B2 (ja) | 脂質ナノ粒子を含む医薬組成物 | |
US20160375134A1 (en) | Modified polynucleotides for the production of secreted proteins | |
US20150050354A1 (en) | Modified polynucleotides for the treatment of otic diseases and conditions | |
JP2015516143A6 (ja) | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160520 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170213 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170302 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170414 |